Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Microsatellite Stable Colorectal Carcinoma: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Microsatellite Stable Colorectal Carcinoma: 1 US clinical trial tracked, none currently recruiting.

Microsatellite Stable Colorectal Carcinoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Compugen, running 1 of these trials.

Enrollment posture brief

Registry condition microsatellite-stable-colorectal-carcinoma

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Microsatellite Stable Co (th…0%
Open-enrollment share among volume-matched conditions near Microsatellite Stable Colorectal Carcinoma

Microsatellite Stable Colorectal Carcinoma has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Microsatellite Stable Colorectal Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Microsatellite Stable Colorectal Carcinoma is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Compugen 1 trials

Named interventions

Most-linked intervention names on Microsatellite Stable Colorectal Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab. Combination
1 trials
Cohort expansion: COM902 in combination with COM701 (both at the RDFE). Drug
1 trials
Cohort expansion: COM902 (RDFE) monotherapy. Drug
1 trials
Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE) Combination
1 trials
Dose escalation: COM902 monotherapy. Drug
1 trials

US sites by state

Facility locations filed on Microsatellite Stable Colorectal Carcinoma trials. A trial with sites in several states counts in each.

Wisconsin 1 trials
Texas 1 trials
Tennessee 1 trials
Ohio 1 trials
Michigan 1 trials
Massachusetts 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Microsatellite Stable Colorectal Carcinoma page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Microsatellite Stable Colorectal Carcinoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Compugen sponsors the most Microsatellite Stable Colorectal Carcinoma trials on record, review their full trial history before evaluating a specific study. See Compugen's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Microsatellite Stable Colorectal Carcinoma condition card totals 1 registered trials; most-linked intervention Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.